Acadia Pharmaceuticals Company Profile (NASDAQ:ACAD)

About Acadia Pharmaceuticals

Acadia Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist (SSIA), targeting 5-HT2A receptors. The Company's Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson's disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist preferentially targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson's disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACAD
  • CUSIP:
Key Metrics:
  • Previous Close: $34.36
  • 50 Day Moving Average: $34.4244
  • 200 Day Moving Average: $30.1757
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.23
  • P/E Growth: -1.6500
  • Market Cap: $3.80B
  • Outstanding Shares: 114,005,000
  • Beta: 3.45
Additional Links:
Companies Related to Acadia Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Acadia Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $46.33 (42.74% upside)

Analysts' Ratings History for Acadia Pharmaceuticals (NASDAQ:ACAD)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2016Piper Jaffray Cos.Reiterated RatingOverweight$44.00View Rating Details
8/10/2016JMP SecuritiesReiterated RatingBuy$45.00View Rating Details
8/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/8/2016HC WainwrightReiterated RatingBuy$60.00View Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00View Rating Details
8/5/2016Needham & Company LLCReiterated RatingBuy$49.00View Rating Details
7/26/2016Cowen and CompanyReiterated RatingOutperform$42.00View Rating Details
6/22/2016Bank of America Corp.DowngradeBuy -> Neutral$40.00View Rating Details
5/22/2016Leerink SwannReiterated RatingHoldView Rating Details
3/28/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
2/6/2015Roth CapitalReiterated RatingBuy$42.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Acadia Pharmaceuticals (NASDAQ:ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)ViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)ViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)ViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acadia Pharmaceuticals (NASDAQ:ACAD)
Current Year EPS Consensus Estimate: $-2.15 EPS
Next Year EPS Consensus Estimate: $-1.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.44)($0.44)($0.44)
Q2 20161($0.46)($0.46)($0.46)
Q3 20161($0.48)($0.48)($0.48)
Q4 20161($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Acadia Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acadia Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Acadia Pharmaceuticals (NASDAQ:ACAD)
DateHeadline
businesswire.com logoACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer - Business Wire (press release) (NASDAQ:ACAD)
www.businesswire.com - August 24 at 11:34 AM
publicnow.com logoACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer (NASDAQ:ACAD)
www.publicnow.com - August 24 at 11:34 AM
businesswire.com logoACADIA Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire (press release) (NASDAQ:ACAD)
www.businesswire.com - August 23 at 8:35 PM
publicnow.com logoACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares (NASDAQ:ACAD)
www.publicnow.com - August 23 at 8:35 PM
News IconTrading the Biotech News: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Opko Health, Inc. (NASDAQ:OPK) - The Voice Registrar (NASDAQ:ACAD)
voiceregistrar.com - August 23 at 3:13 PM
capitalcube.com logoETF’s with exposure to ACADIA Pharmaceuticals, Inc. : August 22, 2016 (NASDAQ:ACAD)
www.capitalcube.com - August 22 at 3:15 PM
News IconNoticeable Insider Trading: ACADIA Pharmaceuticals Inc. (ACAD) - The Voice Registrar (NASDAQ:ACAD)
voiceregistrar.com - August 20 at 3:17 PM
investornewswire.com logoWill ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hit $60 Price Target? - Investor Newswire (NASDAQ:ACAD)
www.investornewswire.com - August 19 at 8:16 PM
News IconIntraday Active Biotech Stocks News: Opko Health, Inc. (NASDAQ:OPK), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - The Voice Registrar (NASDAQ:ACAD)
voiceregistrar.com - August 17 at 3:17 PM
News IconActive biotech company shares in the news: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), PDL BioPharma, Inc ... - The Voice Registrar (NASDAQ:ACAD)
voiceregistrar.com - August 16 at 3:16 PM
insidermonkey.com logoAcadia Pharmaceuticals (ACAD): Baker Bros. Advisors Buys More Shares (NASDAQ:ACAD)
www.insidermonkey.com - August 15 at 10:29 AM
News IconInsider Trading and Recommendation Alert: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Post Registrar (NASDAQ:ACAD)
postregistrar.com - August 14 at 8:03 AM
finance.yahoo.com logoACADIA PHARMACEUTICALS INC Financials (NASDAQ:ACAD)
finance.yahoo.com - August 12 at 3:16 PM
smarteranalyst.com logoStock Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. Prices Public Offering of Common Stock (NASDAQ:ACAD)
www.smarteranalyst.com - August 12 at 11:48 AM
News IconNotable Stock Broker Reports on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (NASDAQ:ACAD)
potiner.com - August 12 at 11:48 AM
fool.com logo5 Can't-Miss Quotes From ACADIA Pharmaceuticals Inc.'s Q2 Investor Call - Motley Fool (NASDAQ:ACAD)
www.fool.com - August 11 at 12:07 PM
fool.com logo5 Can't-Miss Quotes From ACADIA Pharmaceuticals Inc.'s Q2 Investor Call (NASDAQ:ACAD)
www.fool.com - August 11 at 12:07 PM
capitalcube.com logoETF’s with exposure to ACADIA Pharmaceuticals, Inc. : August 10, 2016 (NASDAQ:ACAD)
www.capitalcube.com - August 10 at 9:25 PM
biz.yahoo.com logoACADIA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ACAD)
biz.yahoo.com - August 10 at 9:25 PM
businesswire.com logoACADIA Pharmaceuticals Prices Public Offering of Common Stock - Business Wire (press release) (NASDAQ:ACAD)
www.businesswire.com - August 10 at 11:48 AM
News IconEarnings Analysis of: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - News Oracle (NASDAQ:ACAD)
www.newsoracle.com - August 10 at 11:48 AM
publicnow.com logoACADIA Pharmaceuticals Prices Public Offering of Common Stock (NASDAQ:ACAD)
www.publicnow.com - August 10 at 11:48 AM
finance.yahoo.com logo2:01 am ACADIA Pharmaceuticals prices offering of 6,060,606 shares of its common stock at $33.00 per share (NASDAQ:ACAD)
finance.yahoo.com - August 10 at 11:48 AM
capitalcube.com logoACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:ACAD)
www.capitalcube.com - August 10 at 11:48 AM
News IconAcadia Pharmaceuticals Looking to Raise $200 Million (NASDAQ:ACAD)
www.sdbj.com - August 9 at 8:50 PM
investornewswire.com logoWill ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surprise Analysts? - Investor Newswire (NASDAQ:ACAD)
www.investornewswire.com - August 9 at 3:13 PM
reuters.com logoBRIEF-Acadia Pharmaceuticals announces proposed public offering of common stock - Reuters (NASDAQ:ACAD)
www.reuters.com - August 9 at 3:13 PM
smarteranalyst.com logoStock Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock - Smarter Analyst (NASDAQ:ACAD)
www.smarteranalyst.com - August 9 at 3:13 PM
reuters.com logoBRIEF-Acadia Pharmaceuticals announces proposed public offering of common stock (NASDAQ:ACAD)
www.reuters.com - August 9 at 12:00 PM
smarteranalyst.com logoStock Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock (NASDAQ:ACAD)
www.smarteranalyst.com - August 9 at 12:00 PM
capitalcube.com logoACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : August 9, 2016 (NASDAQ:ACAD)
www.capitalcube.com - August 9 at 12:00 PM
businesswire.com logoACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire (press release) (NASDAQ:ACAD)
www.businesswire.com - August 8 at 8:43 PM
publicnow.com logoACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock (NASDAQ:ACAD)
www.publicnow.com - August 8 at 8:43 PM
smarteranalyst.com logoJMP Analyst Bullish on ACADIA Pharmaceuticals Inc. (ACAD) Following Q2:16 Update; Finds NUPLAZID on Track - Smarter Analyst (NASDAQ:ACAD)
www.smarteranalyst.com - August 8 at 8:03 AM
reuters.com logoBRIEF-Acadia Pharmaceuticals reports Q2 2016 financial results - Reuters (NASDAQ:ACAD)
www.reuters.com - August 6 at 3:15 PM
investornewswire.com logoStrong Sell Calls For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) At 0 - Investor Newswire (NASDAQ:ACAD)
www.investornewswire.com - August 6 at 3:15 PM
streetupdates.com logoAnalysts Review of Stocks: Akorn, Inc. (NASDAQ:AKRX) , ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Street Updates (NASDAQ:ACAD)
www.streetupdates.com - August 5 at 8:40 PM
News IconAnalyst Stock Recommendations For ACADIA Pharmaceuticals Inc ... - TWN (NASDAQ:ACAD)
thewellesleysnews.com - August 5 at 8:40 PM
finance.yahoo.com logoEdited Transcript of ACAD earnings conference call or presentation 4-Aug-16 9:00pm GMT (NASDAQ:ACAD)
finance.yahoo.com - August 5 at 8:40 PM
nasdaq.com logoEarnings Reaction History: ACADIA Pharmaceuticals Inc, 37.5% Follow-Through Indicator, 4.8% Sensitive (NASDAQ:ACAD)
www.nasdaq.com - August 5 at 11:36 AM
News IconACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results (NASDAQ:ACAD)
www.cbs58.com - August 5 at 11:36 AM
twst.com logoACADIA Pharmaceuticals Inc.: ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results (NASDAQ:ACAD)
www.twst.com - August 5 at 11:36 AM
marketwatch.com logo10-Q: ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD)
www.marketwatch.com - August 5 at 11:36 AM
nasdaq.com logoEarnings Reaction History: ACADIA Pharmaceuticals Inc, 37.5% Follow-Through Indicator, 4.8% Sensitive - Nasdaq (NASDAQ:ACAD)
www.nasdaq.com - August 4 at 8:57 PM
smarteranalyst.com logoCompany Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc ... - Smarter Analyst (NASDAQ:ACAD)
www.smarteranalyst.com - August 4 at 8:57 PM
sg.finance.yahoo.com logoAcadia reports 2Q loss (NASDAQ:ACAD)
sg.finance.yahoo.com - August 4 at 8:57 PM
News Icon2 Biotech Stocks News And Price Trends: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cerus Corporation ... - The Voice Registrar (NASDAQ:ACAD)
voiceregistrar.com - August 4 at 3:15 PM
streetupdates.com logoTwo Movers within Analysts Observation: Celgene Corporation (NASDAQ:CELG) , ACADIA Pharmaceuticals Inc ... - Street Updates (NASDAQ:ACAD)
www.streetupdates.com - August 4 at 3:15 PM
biz.yahoo.com logoACADIA Pharmaceuticals Inc Earnings Call (Q2 2016) (NASDAQ:ACAD)
biz.yahoo.com - August 4 at 11:47 AM
biz.yahoo.com logoQ2 2016 ACADIA Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ACAD)
biz.yahoo.com - August 4 at 11:47 AM

Social

Acadia Pharmaceuticals (NASDAQ:ACAD) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff